Virtus Fund Advisers, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Virtus Fund Advisers, LLC
- $26.8 Million
- Q4 2024
A detailed history of Virtus Fund Advisers, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 1,340 shares of CPRX stock, worth $33,366. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,340
Previous 1,294
3.55%
Holding current value
$33,366
Previous $25,000
8.0%
% of portfolio
0.1%
Previous 0.12%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$466 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$212 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$138 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$85.2 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$78.1 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.56B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...